Mayo Foundation for Medical Education and Research

Como Holdings Aps

Como Holding Aps

Cheryl A Conover

Antonio Bayes-Genis

David R Holmes, Iii

Sundeep Khosla

Robert S Schwartz

Francis John Ballard

Peter M Tapley

Claus Oxvig

Kimberly R Kalli

Michael Toft Overgaard

Jan Van Deursen

David R Holmes

Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.

Marker for inflammatory conditions

Methods for diagnosing ovarian neoplasia, monitoring ovarian cancer therapy, and monitoring progression of disease in subjects based on the level of the proform of major basic protein in biological samples from the subjects are described.

Methods of detecting ovarian neoplasia

This document provides materials and methods related to PAPP-A polypeptides, aging, and transgenic non-human mammals whose genomes comprise a disrupted PAPP-A allele. Methods for making such transgenic non-human mammals, and using them and other mammals to identify and characterize agents that affect conditions related to PAPP-A activity, such as vascular restenosis, atherosclerosis, wound healing, cancer, fibrosis, bone development, fetal development, longevity, and fracture repair, also are provided.

Longevity and PAPP-A

The invention provides materials and methods related to a transgenic non-human mammal whose genome comprises a disrupted PAPP-A allele. Methods for making such transgenic non-human mammals, and using them identify and characterize agents that affect conditions related to PAPP-A activity, such as vascular restenosis, atherosclerosis, wound healing, cancer, fibrosis, bone development, fetal development, longevity, and fracture repair, also are provided.

Transgenic mouse lacking PAPP-A activity

Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A) are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents are also described.

Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex

A substantially pure complex including IGFIIE polypeptide and IGFBP2 polypeptide is described. Methods for treating an osteoporosis patient and targeting a compound to the skeletal extracellular matrix of a patient are also described.

Growing community of inventors

Rochester, MN, United States of America

Cheryl A Conover